Entecavir Therapy For Patients With Chronic Hepatitis B Virus Infection And Analysis Of Influencing Factors

Objective:To evaluate the efficacy and analyse the influencing factors of Entecavir therapy for patients with chronic hepatitis B virus infection,and provide the basis for the rational selection of antiviral drugs for clinicians.Methods: A total of 79 patients were collected from the department of infectious diseases in our hospital between August 2014 to February 2015,which were infected with B virus hepatitis(HBV),and given ETV 0.5mg/ day,the liver function,HBV-DNA and hepatitis B virus markers were tested in every three months.Experimental data was calculated and statistical analyzed using SPSS 19.0.Measurement data was presented as mean ± standard deviation of the mean(SD).Normal distribution data using t test,non-normal distribution data with nonparametric test(Wilcoxon signed rank test),Significance was assessed with chi-square tests.A p-value of <0.05 was considered statistically significant.Results:In all 79 patients,the HBV-DNA negative percentage(<500copies/ml)were45.6%?60.8%?81.0%,at week 12,24 and 48,and HBeAg negative rates were higher than those of HBeAg positive.The recovery rate of Alanine aminotransferase(ALT)were67.2%?86.2%?96.6% at week 12,24 and 48,respectively;the recovery rate of Aspartate aminotransferase(AST)were 59.6% ? 85.1% ? 95.7% at week 12,24 and48,respectively;the recovery rate of Total bilirubin(TBIL)were 67.4%?88.4%?97.7% at week 12,24 and 48,respectively;The difference was statistically significant(P<0.05)before and after treatment.The HBeAg negative conversion rate and serum conversion rate were 3.9%,23.5%,31.4% and 0%,5.9%,15.7% at week 12,24 and48,respectively.Gender,age,family history,the baseline of ALT,AST,and TBIL had no response to ETV therapeutic effect(P>0.05).The HBV-DNA negative percentage at initial treatment group and treated group were 52.3% and 14.3%(P<0.05)at week12;64.6%vs42.9%,81.5%vs78.6%(P>0.05)respectively at week 24 and 48;The HBVDNA negative percentages at chronic hepatitis B and cirrhosis were 55.6%vs32.4%?73.3%vs44.1% and 95.6%vs61.8%(P<0.05)respectively at week 12,24 and 48;The HBV DNA negative percentages in HBeAg positive group and HBeAg negative group were 37.3%vs60.7% and 49.0%vs82.1%(P<0.05)respectively at week 12 and 24;and76.5% and 89.3%(P>0.05)respectively at week 48.The HBV-DNA negative percentages in two groups of HBV-DNA?7.00log10copies/ml and HBV-DNA> 7.00log10copies/ml were 61.2%vs20.0%?73.5%vs40.0% and 89.8%vs66.7%(P<0.05)respectively at week12,24 and 48.No obvious adverse reaction was found in 79 patients during the follow-up period and no viral breakthrough and rebound occurred.Conclusion :1 Entecavir was significant effect on treatment chronic hepatitis B virus infection,and adverse reactions were rare.2 Gender,age,family history,the baseline of ALT,AST,and TBIL had no response to ETV therapeutic effect(P>0.05).3 Initial treatment and HBeAg status had a significant effect on the early efficacy of ETV in treating HBV infection,but no significant effect on the long-term outcome.4 Cirrhosis or not,and HBV-DNA loads has some effect with long-term therapy,which could provid prognosis evidence for therapeutic effect.